Generic Name:
selpercatinib
Project Status:
Active
Therapeutic Area:
RET fusion-positive non-small cell lung cancer
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Retevmo
Project Line:
Reimbursement Review
Project Number:
PC0261-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
As monotherapy for the first-line treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
As monotherapy for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and who have received prior systemic therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.